Protocol · Autoimmune & Inflammatory
Takayasu's Arteritis Supportive Care Protocol
Vitamin D and Calcium are the core of this stack, with 6 supporting supplements. Each row gives the amount the protocol lists and the grade our evidence database holds for that supplement in Takayasu's Arteritis Supportive Care.
We are re-verifying the studies cited on protocol pages; only confirmed citations are shown.
The stack
8 supplements · none graded yet
| Grade | Supplement | Amount listed | Why it’s in the stack | Evidence on file |
|---|---|---|---|---|
| Primary stackThe core of this protocol | ||||
| Vitamin D | Amount listed: 2,000–4,000 IU daily (target 40–60 ng/mL); higher doses if deficient | Essential for bone health during corticosteroid treatment; may have immunomodulatory effects | Not graded yet | |
| Calcium | Amount listed: 1,000–1,200 mg daily from diet and supplements combined | Prevents bone loss during long-term corticosteroid treatment | Not graded yet | |
| Supporting stackListed as additions to the core | ||||
| Omega-3 Fatty Acids | Amount listed: 2–3 g EPA+DHA daily | Anti-inflammatory effects may complement immunosuppressive treatment | Not graded yet | |
| Folic Acid | Amount listed: 1–5 mg daily (taken on days without methotrexate) | Essential if taking methotrexate to reduce side effects and maintain folate status | Not graded yet | |
| Coenzyme Q10 | Amount listed: 100–200 mg daily | Supports cardiovascular health; may provide antioxidant protection | Not graded yet | |
| Vitamin C | Amount listed: 500–1,000 mg daily | Antioxidant support; may help with vascular health | Not graded yet | |
| B Vitamins | Amount listed: B-complex daily | Support energy metabolism and may help with fatigue common in chronic illness | Not graded yet | |
| Magnesium | Amount listed: 300–400 mg daily | Supports cardiovascular function and muscle health | Not graded yet | |
How this protocol works
In plain language
Takayasu's arteritis (TAK) is a rare inflammatory disease affecting large blood vessels, primarily the aorta and its major branches. It causes inflammation and thickening of vessel walls, which can lead to narrowing (stenosis), aneurysms, or blockages. This reduces blood flow to organs and limbs, potentially causing symptoms like arm claudication (pain with use), dizziness, visual changes, and weak pulses. It primarily affects young women, typically before age 40. Treatment involves immunosuppressive medications to control inflammation.
CRITICAL: Takayasu's arteritis requires specialized rheumatology care and often vascular surgery collaboration. Treatment includes corticosteroids and other immunosuppressants (methotrexate, azathioprine, biologics like tocilizumab). Disease activity monitoring and imaging are essential. These supplements SUPPORT treatment and address medication side effects but don't replace immunosuppressive therapy.
Vitamin D* is crucial for bone health during long-term corticosteroid treatment, which causes bone loss. It may also have immunomodulatory effects that could benefit autoimmune conditions.
Calcium* works with vitamin D to prevent glucocorticoid-induced osteoporosis, a major concern with chronic steroid use.
Omega-3 Fatty Acids* have anti-inflammatory effects that may complement standard immunosuppressive treatment.
Folic Acid* is essential if you are taking methotrexate (a common treatment). Methotrexate depletes folate, and supplementation reduces side effects like mouth sores, GI upset, and liver enzyme elevations.
CoQ10* supports cardiovascular health, which is relevant given the vascular nature of the disease.
Vitamin C* is an antioxidant that supports vascular health.
B Vitamins* support energy metabolism and may help with the fatigue that often accompanies chronic inflammatory disease.
Magnesium* supports cardiovascular and muscle function.
Expected timeline: Vitamin D and calcium: ongoing protection against bone loss. Folic acid: should be started with methotrexate. Other supplements provide ongoing supportive benefit. Disease control depends on immunosuppressive treatment response.